Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder-Reference-Cited by-同舟云学术

Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder

Published:2020-02-05 Issue:3 Volume:87 Page:347-356
ISSN:0364-5134
Container-title:Annals of Neurology
language:en
Short-container-title:Ann Neurol

Author:

Dauvilliers Yves¹^ORCID,Zammit Gary²,Fietze Ingo³,Mayleben David⁴,Seboek Kinter Dalma⁵,Pain Scott⁵,Hedner Jan⁶

Affiliation:

1. Sleep Unit, Department of Neurology, Neuropsychiatry: Epidemiological and Clinical ResearchUniversity of Montpellier, National Institute of Health and Medical Research, Montpellier University Hospital Center Montpellier France

2. Clinilabs Drug Development Corporation and Icahn School of Medicine at Mount Sinai New York NY

3. Center of Interdisciplinary Sleep MedicineCharité‐Universitätsmedizin Berlin Berlin Germany

4. CTI Clinical Research Center Cincinnati OH

5. Clinical DevelopmentIdorsia Pharmaceuticals Allschwil Switzerland

6. Sahlgrenska University HospitalUniversity of Gothenburg Gothenburg Sweden

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ana.25680

Reference29 articles.

1. Insomnia disorder

2. Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians

3. European guideline for the diagnosis and treatment of insomnia

4. Clinical Guideline for the Evaluation and Management of Chronic Insomnia in Adults

5. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Daridorexant in Japanese patients with insomnia disorder: A phase 3, randomized, double-blind, placebo-controlled study;Sleep Medicine;2024-10

2. Improving Sleep to Address Co-Occurring Substance Use Disorder and Chronic Pain: Exploring the Potential of the Orexin (Hypocretin) System as a Clinical Target;Current Addiction Reports;2024-09-11

3. Dose-response of daridorexant in insomnia disorder: An analysis of Phase 2 and 3 studies;Sleep Medicine;2024-09

4. Distinct bandwidths of orexin neuron activity independently encode body movement and metabolic state;2024-08-16

5. Pharmacokinetics, safety, and efficacy of daridorexant in Japanese subjects: Results from phase 1 and 2 studies;Journal of Sleep Research;2024-08-08